31 results about "B-cell activation" patented technology

The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN®.

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40 / immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.

Disclosed is a method for producing an antibody or an antigen-binding fragment thereof comprising a step of cultivating PBMCs in a medium comprising CD40L, ICOSL, ICOS, and / or TLR agonist. Also provided herein is a method for inducing proliferation of PBMCs, B cell activation and differentiation, and / or B cell maturation, comprising a step of cultivating PBMCs in a medium comprising IL2. Also provided herein is a method for promoting class switch in an antibody-producing PBMC to produce IgG, comprising a step of cultivating the antibody-producing PBMC in a medium comprising IL21.

Disclosed are combination therapies and related compositions that may contain one or more of a p53 potentiating agent, a DNA-damaging agent, an agent that inhibits cell cycle check point, and a pharmaceutically acceptable carrier. Also disclosed are methods of using such compositions for the treatment of conditions related to T cell and / or B cell activation in subjects in need of such treatment.

Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

The invention provides cloning of a chicken CR2 gene, expression and purification of protein and preparation of a polyclonal antibody thereof. An amino acid sequence and a genetic sequence of ChCR2 protein are provided, ChCR2 prokaryotic expression vectors containing different tags are constructed, the ChCR2 protein is expressed by using an escherichia coli prokaryotic expression system, and the protein is purified. The purified protein can be used for preparing polyclonal antibody with higher titer. The ChCR2 gene plays an important role in a chicken immune system. CR2 can link the congenitalcomplement-mediated immune response with pathogen and foreign antigens, and the cell signaling phenomenon caused by the adaptive immune response generated by binding to C3d covalently attached to a target can greatly reduce the threshold value of B cell activation. The position of the B cell in the immune system is very important, so that the ChCR2 discovered by the invention is of great significance in basic research and clinical application.

The invention relates to the technical field of biomedical engineering. At present, the structure, function analysis and transcriptional regulation of the B cell activating factor (BAFF) gene promoter are still blank. The present invention provides five recombinant plasmids containing different lengths of the B cell activating factor (BAFF) gene promoter. It consists of -1349~-1099bp, -1349~-893bp, -1349~-743bp, -1349~-431bp, -1349~-329bp fragments of the upstream promoter sequence of human BAFF gene and without promoter, but containing chloramphenicol acetyl The carrier composition of the base transferase CAT reporter gene, the invention also provides the preparation method and application of the recombinant plasmid. The recombinant plasmids constructed by the present invention containing BAFF gene promoters of different lengths are accurate and reliable, and have laid a foundation for further research on the transcriptional regulation mechanism of human BAFF gene activation; and the method of comparing the transcriptional activity of recombinant promoters with reporter gene activity is simple and can be quantified , is a simple method for screening drugs for antagonism / treatment of SLE at the transcriptional level, and also provides a new target for exploring the prevention and treatment of SLE.

The present invention relates to a method for the treatment of cancer in a subject which comprises the steps of: (i) administering electroporation to a tumour in the subject; and (ii) administering a T or B-cell activating agent to the subject, wherein step (i) and (ii) may be performed in either order.